Dr. V. Craig Jordan's conversations with hundreds of women with breast cancer and his passion to help find a cure for the disease have compelled him to gather eminent cancer specialists to contribute to this book. Distinguished physicians, scientists, breast cancer advocates, and breast cancer survivors have assembled here to answer numerous questions about tamoxifen. Written for both the clinician and patient, this book is a premier source of information about the world's leading drug for the treatment and prevention of breast cancer.
FREE Two-Day Shipping for Students. Learn more |
Book Description
Special Offers and Product Promotions
- Buy $50 in qualifying physical textbooks, get $5 in Amazon MP3 Credit. Here's how (restrictions apply)
Editorial Reviews
About the Author
For more than a quarter of a century, author and editor Dr. V. Craig Jordan has been involved with finding a cure for breast cancer. He has pioneered the evolution of ICI 46,474 from its birth in the laboratory to what is today tamoxifen--the world's most-prescribed drug for the treatment of breast cancer, and the only drug in FDA history approved for the prevention of breast cancer. Dr. Jordan is the recipient of numerous awards, including the prestigious Block Award for Distinguished Achievement in Cancer Research, the Inaugural Brinker International Award for Breast Cancer Research, and the American Society for Pharmacology and Experimental Therapeutics Award for Research on Human Disease. He has also been named Laureate of the Cino del Duca Award for Oncology in Paris (1997).
Excerpt. © Reprinted by permission. All rights reserved.
(from Chapter 15) "It is now apparent that there are two very different levels of risk in women with family histories of breast cancer; one due to a genetically inherited predisposition, and the other associated with an increased familial incidence of breast cancer. At present, mutations in three genes--P53, BRCA-1, and BRCA-2--have been associated with a genetic predisposition to breast cancer." (from Chapter 18) "Five years of tamoxifen reduces the incidence of primary (new) breast cancer in the contralateral breast by 50%. However, the effects of tamoxifen continue to protect the breast even after the drug is stopped."
Product Details
Would you like to update product info or give feedback on images?
|
Customer Reviews
|
Share your thoughts with other customers:
|
||||||||||||||||||||||
|
Most Helpful Customer Reviews
4.0 out of 5 stars
An inside look & detailed analysis!,
By A Customer
This review is from: Tamoxifen for the Treatment and Prevention of Breast Cancer (Hardcover)
"Some of the more highly technical chapters (for instance, those focused on complex scientific research) seem primarily geared toward physicians and other healthcare professionals. Other chapters, however, are highly accessible and should prove particularly informative for patients and their families. Dr. Jordan's comprehensive volume answers a multitude of questions large and small. This book is for anyone wishing to learn more about this important medication."
Share your thoughts with other customers: Create your own review
|
|
Tag this product(What's this?)Think of a tag as a keyword or label you consider is strongly related to this product.
Tags will help all customers organize and find favorite items. |
Sell a Digital Version of This Book in the Kindle Store
If you are a publisher or author and hold the digital rights to a book, you can sell a digital version of it in our Kindle Store.
Learn more
Customer Discussions
|
This product's forum
Active discussions in related forums
Search Customer Discussions
|
Related forums
|
